Larry Emdur, DO
Pulmonary Disease · San Diego, CANPI 1932109642
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Olympus Medical Systems Corporation at 39.4% of the total. 2025 is the largest year on record at $1,100, 4.8 times the $231 reported in 2019.
Across 15 payments — averaging $186.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Medical Systems Corporation$1K
- Covidien LP$750
- BD$550
- AstraZeneca$137
- United Therapeutics Corporation$123
- Tetraphase Pharmaceuticals, Inc.$33
- plus $97 from 5 others
What the payments were for
- Consulting fees$1,11740%
- Speaking & faculty fees$55020%
- Travel & lodging$73326%
- Food & beverage$39014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Medical Systems Corporation | 2 | $1,100 |
| Covidien LP | 1 | $750 |
| BD | 1 | $550 |
| AstraZeneca | 2 | $137 |
| United Therapeutics Corporation | 1 | $123 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $33 |
| Boehringer Ingelheim | 2 | $26 |
| Boston Scientific | 1 | $23 |
| Electromed, Inc. | 2 | $18 |
| AbbVie | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Puritan Bennett$750
- BD BBL Gram Iodine (Stabilized)$550
- FASENRA$123
- TYVASO$123
How this compares
$2,790 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Shari BrazinskySan Diego$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.